ASH 2022 | Investigating LAVA-051 in R/R myeloma and CLL: pharmacodynamic and early clinical cata
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, outlines early results from a Phase I/IIa study that assessed the efficacy of LAVA-051, a novel bispecific gamma-delta T-cell engager in patients with relapsed/refractory (R/R) multiple myeloma and chronic lymphocytic leukemia (CLL). Early clinical data suggest that Lava-051 is well-tolerated and efficacious. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, Astra Zeneca, BMS, Janssen, Roche/Genentech: Research Funding; Janssen, LAVA: Patents & Royalties: Pending; Astra Zeneca, BMS, Roche/Gennetech, Janssen, Abbvie, LAVA: Membership on an entity’s Board of Directors or advisory committees; Abbvie, Astra Zeneca, Janssen: Other: Speakers fee; Amsterdam UMC, University of Amsterdam: Current Employment.
